The "Bring Down Tesla" movement in the United States plans to hold its "largest scale protest" on March 29th

Monnalisa’s delisting from trading on Euronext Growth Milan took effect today. The company is preparing a shareholder buyback process led by Modamet and Jafin Due for investors seeking to sell. Further details are due in coming days on the purchase window and a single settlement date for the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monnalisa S.p.A. published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.

BD will invest $3 billion to expand its manufacturing operations in the United States, aiming to increase the proportion of critical medical supplies sourced domestically to approximately 80%. The agreement links the company’s U.S. manufacturing commitments to tariff relief. Information about the stock price was added in the third paragraph, analyst commentary in the sixth paragraph, and background information in the eleventh paragraph. Siddhi Mahatole, Reuters, October 6 — Becton Dickinson and Company (BDX.N) has become the first major U.S. medical device manufacturer to sign an agreement with the U.S. government to expand domestic manufacturing, with a pledge to invest $19 billion in the coming years in exchange for protection against future tariffs. Under the agreement, the company said on Tuesday it plans to make capital, operational, and supply chain investments in the U.S., with $3 billion specifically allocated to strategic manufacturing facilities across the country. Shares of the medical device maker rose 2.4% in early trading. This deal is one of several measures by the Trump administration to encourage domestic healthcare manufacturing through the threat of tariffs, with several major pharmaceutical companies having already committed billions of dollars toward building and expanding production and R&D facilities in the U.S. The agreement ties BD’s U.S. manufacturing commitments to future exemptions from tariffs on related products and raw materials under Section 232, depending on the final scope of the measures and whether the company achieves agreed-upon milestones. Jefferies analyst Matthew Taylor commented, “We believe clarity on tariff policy, or tariff impacts being potentially ‘not as bad as feared,’ could be an inflection point for the medtech sector.” He added, “We are curious if there are more medtech-related announcements pending.” The company plans to increase annual U.S. production by around 5 billion basic medical supply units, raising the domestic supply share to roughly 80%. BD also intends to use U.S.-made steel to manufacture all needles for the U.S. market domestically. Becton Dickinson stated that, as the final tariff rates, product range, and implementation timelines remain undetermined, the financial impact of the agreement has not been quantified yet. This announcement builds on President Donald Trump’s Monday statement that the company has agreed to invest $3 billion to shift basic medical product manufacturing to the U.S., with more than $1 billion allocated to Nebraska. In January this year, Becton Dickinson announced a $110 million investment to expand the production of prefilled syringes and needles in Columbus, Nebraska, expected to create about 120 jobs. Syringe products are expected to start shipping to customers by mid-2026.